The word “blockbuster” gets thrown around quite a bit when it comes to prescription drugs. But now, the blockbuster status of Invega Sustenna, an injectible antipsychotic drug used to treat schizophrenia and related disorders, is a matter of public record.

In an opinion unsealed this week, U.S. District Judge Claire Cecchi in Newark, New Jersey dubbed the drug a “blockbuster” while finding the sole patent that covers it valid. The judge noted the drug netted sales of $1.7 billion in 2019 alone for Johnson & Johnson subsidiary Janssen. The decision, which comes after a three-week bench trial held completely remotely in October 2020, turns back an attempt by generic maker Teva Pharmaceuticals to launch its own competing product.